Abbott Laboratories (ABT) Q2 2026 earnings

Published Jul 16, 2026

AI summary

Adjusted EPS $1.31 beat the $1.28 consensus by $0.03, up from $1.26 a year ago.
Abbott reported second-quarter sales of $12.59 billion, a 13.0 percent increase on a reported basis.
The company achieved GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31 for the quarter.
Medical Devices sales grew 9.0 percent, led by strong performance in Electrophysiology and Diabetes Care.
Management raised its full-year 2026 adjusted diluted EPS guidance range to between $5.45 and $5.60.

Revenue

Not reported in this release.

Adjusted EPS

Reported · adjusted diluted EPS

$1.31

Consensus $1.28

Beat by $0.03

GAAP EPS: $0.53

Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.

$5.45–$5.60

full-year 2026 EPS guidance (non-GAAP)

Next-quarter consensus not captured before release.

Worldwide Nutrition sales decreased 3.1 percent on a reported basis during the quarter.
Results include the impact of the Exact Sciences acquisition completed on March 23, 2026.

Source: Abbott Laboratories press release · SEC Form 8-K exhibit 99.1

Figures as stated in the company’s release; consensus from the provider named above. Not financial advice.